The post Global Heart Valve Devices Market: Trends, Opportunities, and Forecast (2022-2032) appeared first on Newstrail.com authored by Fact.MR

The global heart valve devices market is expected to grow at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2022-2032. The rising prevalence of cardiovascular diseases, growing geriatric population, and increasing demand for minimally-invasive surgeries are some of the major factors driving the market growth. Moreover, the increasing awareness regarding the advantages of heart valve replacement devices and technological advancements in cardiovascular surgery are also expected to fuel the market growth.

By type, the market is segmented into bioprosthetic heart valves, mechanical heart valves, and transcatheter heart valves. Bioprosthetic heart valves are expected to account for the largest market share, owing to the increasing demand for non-invasive surgeries, and rising geriatric population. Moreover, the development of advanced and cost-effective heart valves is expected to propel the segment growth over the forecast period.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4759?VM

Key Companies Profiled

• Edwards Lifesciences Corporation
• Braile Biomedica
• St. Jude Medical Inc.
• Medical Technology Est.
• Micro Interventional Devices Inc.
• Boston Scientific Corporation
• Liva Nova PLC
• Cryolife, Inc.
• Jena Valve Technology Inc.

Competitive Landscape

The competitive landscape of the global heart valve devices market is highly fragmented, with several established players competing for market share. The major players in this market are Edwards Lifesciences Corporation, Boston Scientific Corporation, Medtronic Plc., Abbot Laboratories, LivaNova Plc., CryoLife Inc., and Micro Interventional Devices Inc. These players have adopted various strategies such as product launches, product development, acquisition, collaboration, and merger to gain a competitive edge in the market.

For instance, in April 2021, Edwards Lifesciences Corporation launched the Edwards SAPIEN 3 Ultra transcatheter heart valve, a new generation of transcatheter aortic valve replacement (TAVR) systems, to treat severe aortic stenosis. Similarly, in August 2020, Medtronic Plc. launched the CoreValve 3D Repositionable valve, a third-generation transcatheter aortic valve replacement device, in the United States.

Furthermore, in April 2020, Abbott Laboratories launched the Tendyne transcatheter mitral valve, a next generation device, in the European Union. This device is intended for the treatment of severe, symptomatic mitral regurgitation in patients who are at high or extreme risk for mitral valve surgery.

Get Full Access of Complete Report:
https://www.factmr.com/checkout/4759

Recent developments in Heart Valve Devices Market

Recent developments in the heart valve devices market include the development of transcatheter aortic valve replacement (TAVR) systems, minimally invasive cardiac valve replacement systems, and magnetic mitral valve replacement systems. TAVR systems are designed to replace the diseased aortic valve and restore normal blood flow without the need for open-heart surgery.

This minimally invasive procedure is increasingly being used in patients with severe aortic stenosis, and has been demonstrated to improve patient outcomes. Magnetic mitral valve replacement systems are designed to replace the mitral valve without the need for open-heart surgery. These systems use magnets to anchor the replacement valve in place, enabling a more precise repair of the valve without the need for sutures. Additionally, advances in 3D printing technologies have enabled the development of personalized heart valves, which are designed to match the patient’s anatomy and provide a better fit than traditional valves.